During the past decade, Institute for Translational Oncology Research conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 2 clinical trials were completed, i.e. on average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Institute for Translational Oncology Research" #1 sponsor was "BioVex Limited" with 1 trials, followed by "Boehringer Ingelheim" with 1 trials sponsored, "Compass Therapeutics" with 1 trials sponsored, "Sumitomo Pharma Oncology, Inc." with 1 trials sponsored and "Threshold Pharmaceuticals" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Institute for Translational Oncology Research" #1 collaborator was "Amgen" with 1 trials as a collaborator, "Iqvia Pty Ltd" with 1 trials as a collaborator, "Merck, Sharp & Dohme, LLC, Rahway, NJ USA" with 1 trials as a collaborator and "PRA Health Sciences" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Institute for Translational Oncology Research" are "Melanoma" (2 trials), "Bronchiectasis" (1 trials), "Cancer" (1 trials), "Head and Neck Cancer" (1 trials) and "Locally Advanced Solid Tumor" (1 trials). Many other conditions were trialed in "Institute for Translational Oncology Research" in a lesser frequency.

Most popular intervention types in "Institute for Translational Oncology Research" are "Drug" (4 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "BBI608" (1 trials), "BI 1291583" (1 trials), "CTX-471" (1 trials), "GM-CSF" (1 trials) and "Gemzar (Gemcitabine)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Institute for Translational Oncology Research" are 5 trials for "All" genders.

Currently, there are NaN active trials in "Institute for Translational Oncology Research". undefined are not yet recruiting, 2 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Institute for Translational Oncology Research, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Institute for Translational Oncology Research, 2 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".